Mesoblast Ltd ADR MESO
News
Mesoblast Showcased at ASX Premier Investor Day Event
Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar
Mesoblast Board Changes
Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
Mesoblast Reports Substantial Revenue Growth to US$120M
Mesoblast Financial Results and Corporate Update Webcast
